SCHEMBL3008528

SCHEMBL3008528

Cc1ccc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
KCNH2 Q12809 1/20 0.37
EPHX2 P34913 1/20 0.35
DNM1L O00429 5/20 0.34
MAPT P10636 5/20 0.34
TP53 P04637 2/20 0.34
LMNA P02545 2/20 0.34
SCN1A P35498 2/20 0.34
SCN8A Q9UQD0 2/20 0.34
HTT P42858 2/20 0.34
GBA1 P04062 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017996 0.92 LMNA (0.35) DNM1LMAPTTP53LMNAHTT
SCHEMBL3013654 0.91 DRD2 (0.39) DRD2HTR2AHTR2CKCNH2EPHX2
SCHEMBL3001160 0.91 DRD2 (0.38) DRD2HTR2AHTR2CKCNH2EPHX2
SCHEMBL3007243 0.89 MAPT (0.36) DRD2HTR2AHTR2CKCNH2DNM1L
SCHEMBL3002470 0.89 TP53 (0.38) DRD2HTR2AHTR2CKCNH2DNM1L
SCHEMBL3004883 0.89 HTR2A (0.40) DRD2HTR2AHTR2CKCNH2EPHX2
SCHEMBL3011496 0.88 GBA1 (0.42) DNM1LMAPTHTTGBA1ALDH1A1
SCHEMBL3008920 0.88 RAB9A (0.38) DNM1LMAPTTP53LMNAHTT
SCHEMBL3012839 0.88 DNM1L (0.35) DRD2HTR2AHTR2CKCNH2EPHX2
SCHEMBL2998218 0.87 DRD2 (0.37) DRD2HTR2AHTR2CKCNH2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DRD2 573/4885HTR2A 752/4885HTR2C 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.